Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

Código QR

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

Daniel Q Holland, Joshua J NeumillerDepartment of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington, USAAbstract: Alogliptin is a selective dipeptidyl peptidase-4 inhibitor recently marketed for once-daily administration in the treatment of type 2 diabetes melli...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Holl, DQ, Neumiller JJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/53402642e95245d494c8940a9115b18a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin
por: Ohira M, et al.
Publicado: (2014)

Risk management in the treatment of type 2 diabetes with pioglitazone
por: Giuseppe Derosa, et al.
Publicado: (2009)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Stanley S Schwartz
Publicado: (2010)

Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
por: Irons BK, et al.
Publicado: (2014)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Jonathan K Reynolds
Publicado: (2009)

Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated [Corrigendum]
por: Irons BK, et al.
Publicado: (2017)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
por: Robert Moses
Publicado: (2009)

Clinical utility of fixed combinations of sitagliptin&ndash;metformin in treatment of type 2 diabetes
por: Karen Barnard, et al.
Publicado: (2010)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Shannon A Miller, et al.
Publicado: (2009)

Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
por: Fleming JW, et al.
Publicado: (2015)

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
por: Maffioli P, et al.
Publicado: (2011)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Radha Andukuri, et al.
Publicado: (2009)

Long-term (52&ndash;78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients
por: Bays HE
Publicado: (2012)

Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects
por: Kapoor S
Publicado: (2012)

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
por: Robert G Moses
Publicado: (2010)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
por: Schwartz S
Publicado: (2010)

Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment
por: M. V. Shestakova, et al.
Publicado: (2021)

Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγnull mice treated with alogliptin
por: Jurczyk A, et al.
Publicado: (2013)

Combination of Metformin and Exercise in Management of Metabolic Abnormalities Observed in Type 2 Diabetes Mellitus
por: Jevtovic F
Publicado: (2021)

Metformin Treatment: A Potential Cause of Megaloblastic Anemia in Patients with Type 2 Diabetes Mellitus
por: Albai O, et al.
Publicado: (2020)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen AB, et al.
Publicado: (2013)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Joshua J Neumiller, et al.
Publicado: (2010)

Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
por: Konya H, et al.
Publicado: (2013)

Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial
por: Zhang F, et al.
Publicado: (2021)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Green J, et al.
Publicado: (2010)

Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus
por: Xie J, et al.
Publicado: (2019)

Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus
por: Zhang Q, et al.
Publicado: (2020)

Sexual dysfunction in diabetic women: prevalence and differences in type 1 and type 2 diabetes mellitus
por: Mazzilli R, et al.
Publicado: (2015)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Pamela Kushner
Publicado: (2010)

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
por: Feher M, et al.
Publicado: (2013)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto S, et al.
Publicado: (2015)

Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
por: Lorber D
Publicado: (2014)

Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention
por: Alaa Badawi, et al.
Publicado: (2010)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
por: Stanley Schwartz, et al.
Publicado: (2010)

Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage [Corrigendum]
por: Wilke T, et al.
Publicado: (2019)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Jason Seewoodhary, et al.
Publicado: (2010)

Holistic approach to prevention and management of type 2 diabetes mellitus in a family setting
por: Ofori SN, et al.
Publicado: (2014)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
por: Whaley JM, et al.
Publicado: (2012)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
por: Rigato M, et al.
Publicado: (2014)

Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements
por: Yang F, et al.
Publicado: (2015)